Huayi Li

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Chimeric antigen receptor (CAR)‐T cell therapy is largely ineffective in most solid tumors, partially because of inadequate intratumoral trafficking. Bridging therapy, administered between leukapheresis and CAR‐T cell infusion, offers a distinct opportunity to control the disease and precondition the tumor microenviron...